Trial Information

Summary: A Randomized, Double-blind, Placebo-controlled Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

A 14 week, double-blind study using Verapamil R for treatment of Irritable Bowel Syndrome with Diarrhea. All subjects will need to complete dialy diary entries by phone in conjunction with office visits to the site.

Patient Inclusion Criteria:

• 18 - 70 years old
• DIARRHEA predominant with symptoms for at least the past 3 months

Patient Exclusion Criteria:

• Cardiovascular disease where treatment with Verapamil is contraindicated
• Celiac disease, acute diverticulitis or duodenal ulcers
• Barrett’s or grade 3 esophagitis
• Crohn’s disease, ulcerative colitis or severe GERD

If you would like to learn more about participating in this study, please send an e-mail message using the form below.